S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:LYRA

Lyra Therapeutics Stock Forecast, Price & News

$13.66
-0.37 (-2.64 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.45
Now: $13.66
$14.02
50-Day Range
$10.57
MA: $12.48
$15.61
52-Week Range
$8.76
Now: $13.66
$22.00
Volume107,314 shs
Average Volume181,824 shs
Market Capitalization$176.58 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
Lyra Therapeutics logo

Headlines

Lyra Therapeutics EPS misses by $0.05
November 10, 2020 |  seekingalpha.com
Lyra Therapeutics, Inc. (LYRA)
October 14, 2020 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LYRA
CUSIPN/A
CIKN/A
Phone617-373-4600
Employees33
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$176.58 million
Next Earnings Date3/9/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

406th out of 1,972 stocks

Surgical & Medical Instruments Industry

36th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$13.66
-0.37 (-2.64 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LYRA News and Ratings via Email

Sign-up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lyra Therapeutics (NASDAQ:LYRA) Frequently Asked Questions

Is Lyra Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Lyra Therapeutics stock.
View analyst ratings for Lyra Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Lyra Therapeutics?

Wall Street analysts have given Lyra Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lyra Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Lyra Therapeutics' next earnings date?

Lyra Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Lyra Therapeutics
.

How can I listen to Lyra Therapeutics' earnings call?

Lyra Therapeutics will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.49) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.08.
View Lyra Therapeutics' earnings history
.

What price target have analysts set for LYRA?

4 analysts have issued 12 month price objectives for Lyra Therapeutics' stock. Their forecasts range from $24.00 to $28.00. On average, they expect Lyra Therapeutics' share price to reach $26.00 in the next year. This suggests a possible upside of 90.3% from the stock's current price.
View analysts' price targets for Lyra Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Lyra Therapeutics' key executives?

Lyra Therapeutics' management team includes the following people:
  • Dr. Maria Palasis Ph.D., Chair of the Board, CEO & Pres (Age 56, Pay $523.83k)
  • Mr. R. Donald Elsey, CFO, Treasurer & Sec. (Age 67, Pay $367.16k)
  • Dr. Carmichael S. Roberts Jr., Co-Founder (Age 53)
  • Mr. Ray Knox, VP of Operations
  • Ms. Corinne Noyes, Sr. VP of Commercial Strategy & Market Devel. (Age 53)
  • Ms. Vineeta Belanger Ph.D., Sr. VP of Clinical Affairs
  • Dr. Robert Richard Ph.D., Sr. VP of R&D
  • Ms. Pamela E. Nelson, Sr. VP of Regulatory Affairs
  • Mr. Robert M. Solomon, Assistant Sec.

Who are some of Lyra Therapeutics' key competitors?

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

When did Lyra Therapeutics IPO?

(LYRA) raised $52 million in an initial public offering (IPO) on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

What is Lyra Therapeutics' stock symbol?

Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA."

Who are Lyra Therapeutics' major shareholders?

Lyra Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ikarian Capital LLC (6.31%), BlackRock Inc. (2.04%), JPMorgan Chase & Co. (1.48%), Northern Trust Corp (0.53%), Bank of New York Mellon Corp (0.15%) and Charles Schwab Investment Management Inc. (0.11%). Company insiders that own Lyra Therapeutics stock include Edward T Anderson and Polaris Venture Partners Speci.
View institutional ownership trends for Lyra Therapeutics
.

Which institutional investors are buying Lyra Therapeutics stock?

LYRA stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, JPMorgan Chase & Co., BlackRock Inc., Northern Trust Corp, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, Wells Fargo & Company MN, and American International Group Inc.. Company insiders that have bought Lyra Therapeutics stock in the last two years include Edward T Anderson, and Polaris Venture Partners Speci.
View insider buying and selling activity for Lyra Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyra Therapeutics' stock price today?

One share of LYRA stock can currently be purchased for approximately $13.66.

How much money does Lyra Therapeutics make?

Lyra Therapeutics has a market capitalization of $176.58 million.

How many employees does Lyra Therapeutics have?

Lyra Therapeutics employs 33 workers across the globe.

What is Lyra Therapeutics' official website?

The official website for Lyra Therapeutics is www.lyratherapeutics.com.

Where are Lyra Therapeutics' headquarters?

Lyra Therapeutics is headquartered at 480 ARSENAL STREET, WATERTOWN MA, 02472.

How can I contact Lyra Therapeutics?

Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The company can be reached via phone at 617-373-4600 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.